See more : Mahaan Foods Limited (MAHAANF.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Intec Pharma Ltd (NTEC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intec Pharma Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- MedTech Acquisition Corporation (MTACW) Income Statement Analysis – Financial Results
- Ensurge Micropower ASA (0JI9.L) Income Statement Analysis – Financial Results
- Jiu Rong Holdings Limited (2358.HK) Income Statement Analysis – Financial Results
- GlucoTrack, Inc. (IGAP) Income Statement Analysis – Financial Results
- Hunan Yussen Energy Technology Co., Ltd. (002986.SZ) Income Statement Analysis – Financial Results
Intec Pharma Ltd (NTEC)
About Intec Pharma Ltd
Intec Pharma Ltd, a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various pain indications. Intec Pharma Ltd. has a research collaboration agreement with Merck to explore using the Accordion Pill platform for development program. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd in March 2004. Intec Pharma Ltd was founded in 2000 and is based in Jerusalem, Israel.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.74M | 26.66M | 35.40M | 24.30M | 10.75M | 4.79M | 3.41M | 2.59M |
| General & Administrative | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.09M | 8.29M | 7.93M | 5.12M | 3.07M | 2.75M | 2.59M | 2.74M |
| Other Expenses | 0.00 | -1.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 13.83M | 33.45M | 43.33M | 29.41M | 13.82M | 7.54M | 6.00M | 5.33M |
| Cost & Expenses | 13.83M | 33.45M | 43.33M | 29.44M | 13.85M | 7.56M | 6.02M | 5.36M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 15.00K | 23.00K | 17.00K | 16.00K | 15.37K | 23.00K | 24.41K |
| Depreciation & Amortization | 1.20M | 854.00K | 859.00K | 829.00K | 701.00K | 742.38K | 585.00K | 624.84K |
| EBITDA | -12.80M | -46.09M | -42.56M | -28.22M | -12.65M | -6.39M | -5.09M | -4.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.83M | -33.45M | -43.33M | -29.44M | -13.85M | -7.56M | -6.02M | -5.36M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -175.00K | -13.52M | -112.00K | 375.00K | 484.00K | 421.40K | 325.00K | 74.66K |
| Income Before Tax | -14.00M | -46.96M | -43.44M | -29.06M | -13.36M | -7.14M | -5.69M | -5.28M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 124.00K | 638.00K | 103.00K | 29.00K | 500.00K | 436.77K | 348.00K | 99.07K |
| Net Income | -14.13M | -47.60M | -43.54M | -29.09M | -13.36M | -7.14M | -5.69M | -5.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| EPS Diluted | -14.30 | -112.74 | -111.67 | -131.79 | -93.38 | -73.35 | -94.39 | -97.75 |
| Weighted Avg Shares Out | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
| Weighted Avg Shares Out (Dil) | 988.00K | 422.20K | 389.91K | 220.75K | 143.10K | 97.39K | 60.31K | 54.03K |
Intec Announces Expected Closing Date of Decoy Merger
NTEC Stock: 10 Things to Know About Red-Hot Intec Pharma
3 Biotech Penny Stocks To Watch On Robinhood IPO Day
Hot Penny Stocks to Buy Now? 4 You Need to Know About
Best Penny Stocks To Buy Before Marijuana Legalization? 4 To Watch Now
Top 10 Biotech Penny Stocks to Watch in July 2021
Best Penny Stocks To Buy Now? 7 To Watch This Week
The Week Where New York Legalizes Recreational Marijuana
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Intec Pharma Ltd. - NTEC
SHAREHOLDER ALERT: WeissLaw LLP Investigates Intec Pharma Ltd.
Source: https://incomestatements.info
Category: Stock Reports